As of March 31, 2017, Mylan Pharmaceuticals has issued a voluntary recall for Epi Pen and Epi Pen Jr, epinephrine autoinjectors, from 13 specified lots.
The recall is due to a potential defective part that would result in the devices’ failure to activate. Although there have been a small number of defective devices reported, Mylan is taking proactive actions to ensure the safety of their products.
The recalled products were distributed between Dec. 17, 2015 and July 1, 2016. Please check your epinephrine autoinjectors and compare with the Mylan Site for lot numbers and steps to return and replace your defective epinephrine autoinjector.
For additional information please view the FDA’s official press release, here.
You may also be interested in . . .
Botanical Sexism: Does it impact allergy sufferers?
What is Botanical Sexism? Tom Ogren, horticulturist and allergy researcher, has done extensive research on ways to reduce pollen counts and pollen…
New Report Shows Most States Fall Behind on Asthma and Allergy School Policies
With millions of children heading back to classrooms in the coming weeks, asthma and food allergies at school present serious concerns, but some states…